Notice: Prescription Drug List (PDL): Multiple Additions

Date: October 7, 2019 Our file number: 19-119291-196 The purpose of this Notice of Amendment is to notify about the additions of acalabrutinib, galcanezumab, larotrectinib, mannitol, neratinib, niraparib, ravulizumab, romosozumab, and sodium zirconium cyclosilicate to the Prescription Drug List (PDL) for human and veterinary use. These additions are effective at the time of posting. Rationale: A scientific review of these drugs against the criteria set out in

An Update from Clinical Trials Ontario

Clinical Trials Ontario (CTO) has been working with health charities and patient organizations like CCSN to build tools and resources about clinical trials that are informed by and meet the needs of their communities. CCSN is one of the organizations that has been engaged from the start of these efforts, and this update is intended to help you see what this collaborative work has produced.

Where Do Canada’s MP Candidates Stand on Cancer Issues?

Ahead of the federal election, CCSN believes in the critical importance of raising key issues related to the mission of creating and maintaining the best standard of care for cancer patients, survivors and caregivers. As part of these efforts, CSSN has asked the parties and candidates for their stance on the following issues: Employment Insurance Sickness Benefits National Pharmacare Program Youth Vaping Breast Cancer Screening

Patient Group Engagement in Public Policy: the Convergence of Experience, Influence and Opportunity

CCSN President & CEO Jackie Manthorne was one of several speakers at the Ontario Lung Association Breathing Policy Forum on Patient Engagement in Public Policy held in Toronto on Sept. 18, 2019. During this forum on patient group engagement within the drug submission process and patient group engagement within national Pharmacare, Manthorne presented information about CCSN and the dozens of patient group submissions that CCSN